| abstract |
The present invention relates to at least one cardiovascular compound comprising at least one nitric oxide enhancing group or a pharmaceutically acceptable salt thereof, and optionally at least one nitric oxide enhancing compound and / or at least one therapeutic agent. Including compositions and kits are described. The present invention includes (a) treating cardiovascular disease; (b) treating renovascular disease; (c) treating diabetes; (d) treating disease resulting from oxidative stress; (e) endothelium. Treat dysfunction; (f) treat disease caused by endothelial dysfunction; (g) treat cirrhosis; (h) treat pre-eclampsia; (Q) treat osteoporosis; (k) kidney (L) treat peripheral vascular disease; (m) treat portal hypertension; (n) treat ophthalmic disease; (o) treat metabolic syndrome; and (p) A method of treating hyperlipidemia is also provided. Cardiovascular compounds are angiotensin II antagonists, aldosterone antagonists, endothelin antagonists, hydralazine compounds, neutral endopeptidase inhibitors, and renin inhibitors. Nitric oxide enhancing groups are nitroxides and / or heterocyclic nitric oxide donors. |